1. Introduction {#sec1}
===============

Management of coronary disease has evolved immensely over the past 40 years. Coronary artery bypass grafting (CABG) has become less common with the development of percutaneous coronary intervention (PCI). PCI has now become standard of care for managing patients with myocardial infarction (MI), with stenting techniques replacing balloon angioplasty. The increased role of stenting has led to the development of drug-eluting stents which have been shown to lower restenosis rates when compared to bare metal stents, without increasing the risk of MI or death \[[@B1]\]. There are various options when selecting drug-eluting stents, including paclitaxel-, sirolimus, and zotarolimus-eluting stents. With several options when it comes to drug-eluting stents, the need for evidence-based guidelines has become evident. This meta-analysis pools data from studies comparing 12-month clinical outcomes of newer zotarolimus-eluting stents to commonly used paclitaxel-eluting stents.

2. Methods {#sec2}
==========

2.1. Literature Sources, Search Terms, and Study Selection {#sec2.1}
----------------------------------------------------------

Systematic review of medical literature was carried out to identify studies evaluating outcomes after stenting with zotarolimus- and paclitaxel-eluting stents. Studies were collected by searching MEDLINE and the Cochrane Library using web-based search engines such as OVID. All relevant studies were assessed for inclusion regardless of time of publication. Search terms used include zotarolimus, paclitaxel, drug-eluting stents, stent thrombosis, stent outcomes, and combinations of these terms. Hand search for articles, abstracts, and reviews was also conducted using references of already identified studies. Explicit inclusion and exclusion criteria were used to evaluate the titles and abstracts from collected articles on basis of the aforementioned criteria for potential inclusion. [Figure 1](#fig1){ref-type="fig"} outlines study selection.

2.2. End Points and Definitions {#sec2.2}
-------------------------------

A total of seven end points were extracted from five studies \[[@B2]--[@B6]\]. End points studied were myocardial infarction (MI), major adverse cardiac events (MACE), cardiac death, all-cause death, stent thrombosis, target vessel revascularization, and target lesion revascularization. Only studies with corresponding endpoint definitions were included.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

After articles were collected and screened for inclusion, full articles were retrieved for titles thought to fulfill inclusion criteria. Data was then extracted while also scoring the methodological quality of each study.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Individual patient data from included studies was not available, so a meta-analysis was done using summary statistics from each. Statistical analysis was performed using the MedCalc software package (Version 11.3, Mariakerke, Belgium). Cochrane\'s Q statistics were calculated and used to determine the heterogeneity of the studies for each end point. The end points demonstrated homogeneous results so the fixed effects model was used for analysis ([Table 1](#tab1){ref-type="table"}). A two-sided alpha error less than 0.05 was considered to be statistically significant. Heterogeneity analysis is summarized in [Table 1](#tab1){ref-type="table"}.

3. Results {#sec3}
==========

3.1. Baseline Characteristics {#sec3.1}
-----------------------------

The characteristics of each individual trial had no significant differences within studies ([Table 2](#tab2){ref-type="table"}). Results of the meta-analysis are shown in Figures [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}. There were no significant differences in patient demographics between both groups.

3.2. Myocardial Infarction {#sec3.2}
--------------------------

There was a significant decrease in risk of myocardial infarction in the zotarolimus group (odds ratio, 0.250, confidence interval, 0.160 to 0.392).

3.3. Major Adverse Cardiac Events {#sec3.3}
---------------------------------

There was a slightly lower risk of major adverse cardiac events in the zotarolimus group; this finding, however, is statistically insignificant (odds ratio, 0.813, confidence interval, 0.656 to 1.007).

3.4. Cardiac Death {#sec3.4}
------------------

There was a slightly lower risk of cardiac death in the zotarolimus group; this finding, however, is statistically insignificant (odds ratio, 0.817, confidence interval, 0.359 to 1.857).

3.5. All-Cause Death {#sec3.5}
--------------------

There was a slightly lower risk of all-cause death in the zotarolimus group; this finding, however, is statistically insignificant (odds ratio, 0.820, confidence interval, 0.443 to 1.516).

3.6. Stent Thrombosis {#sec3.6}
---------------------

There was a slightly higher risk of stent thrombosis in the zotarolimus group; this finding, however, is statistically insignificant (odds ratio, 1.174, confidence interval, 0.604 to 2.280).

3.7. Target Vessel Revascularization {#sec3.7}
------------------------------------

There was a significantly higher risk of target vessel revascularization in the zotarolimus group (odds ratio, 1.336, confidence interval, 1.003 to 1.778).

3.8. Target Lesion Revascularization {#sec3.8}
------------------------------------

Risk of target lesion was lower in the zotarolimus group; this finding, however, is statistically insignificant (odds ratio, 0.936, confidence interval 0.702 to 1.247).

4. Discussion {#sec4}
=============

This meta-analysis shows that zotarolimus-eluting stents may not differ with respect to outcomes studied here. Other studies have had similar results with these particular outcomes when comparing zotarolimus- and paclitaxel-eluting stents \[[@B3]--[@B5]\]. A two-year follow-up study by Cicek et al., however, did find a statistically significant decrease in MACE, coronary artery bypass graft, and Q wave MI, associated with zotarolimus-eluting stents when compared to paclitaxel-eluting stents. No major differences were reported by this study for all-cause death, target vessel revascularization, and non-target-vessel revascularization \[[@B7]\]. This study was nonrandomized and had a small number of patients; so the true value of these findings is questionable. Where the two stent varieties do seem to differ is in late loss, an end point not included in this 12-month outcome meta-analysis. Zotarolimus-eluting stents have been documented to demonstrate greater late loss than paclitaxel-eluting stents \[[@B2], [@B3], [@B8]\]. This study, however, did not find an increase in stent thrombosis with zotarolimus-eluting stents.

Drug-eluting stents have significantly reduced the rate of restenosis when compared to bare metal stents \[[@B9]\] and have assumed a larger role in the management of STEMI as primary percutaneous coronary intervention has become standard of care. When compared to bare metal stents, drug-eluting stents have shown greater 1-year event-free survival rates \[[@B10]--[@B12]\] and similar safety profiles \[[@B13], [@B14]\] in STEMI patients. Sirolimus- and paclitaxel-eluting stents have been used with success for primary PCI in standard STEMI cases as well as those complicated by anatomical variations \[[@B15]\].

The ENDEAVOR IV trial studied the cost-effectiveness of zotarolimus-eluting stents and concluded that cost-effectiveness was similar to that of paclitaxel-eluting stents. Analysis took into account quality-adjusted survival, medical costs, and relative cost-cost effectiveness \[[@B24]\].

While zotarolimus-eluting stents have been associated with greater in-stent late loss when compared to paclitaxel-eluting stents, this may not have much clinical impact as studies have noted that low mean values of in-stent late loss are not associated with the risk of stent thrombosis \[[@B25]\].

Limitations of this meta-analysis include those inherent to all such analyses such as pooling of data from studies which may have slightly differing designs and heterogeneity. It should also be noted that ZoMaxx I included only 9-month follow-up data which was included in this study. As with any meta-analysis, publication and selection bias may have impacted results of this analysis.

5. Conclusion {#sec5}
=============

The zotarolimus-eluting stents offer a safe option when selecting a drug-eluting stent. When compared to paclitaxel-eluting stents, zotarolimus eluting stents are associated with a significantly lower risk of myocardial infarction while being associated with a significantly higher risk of need for target vessel revascularization. Additionally, studies have shown increased late loss in zotarolimus-eluting stents when compared to paclitaxel-eluting stents. This increased late loss should be kept in mind when zotarolimus-eluting stents are being considered. Comparison of 12-month outcomes does not seem to warrant the use of either stent over the other, particularly keeping in mind the absence of any advantage afforded by one stent in regards to cost-effectiveness.
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CABG:

:   Coronary artery bypass graft

MI:

:   Myocardial infarction

MACE:

:   Major adverse cardiac events

STEMI:

:   ST-elevation myocardial infarction

PCI:

:   Percutaneous coronary intervention.
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###### 

Summary of heterogeneity analysis.

                                    *Q*      *dF*   *P*-value   Result
  --------------------------------- -------- ------ ----------- ------------
  MI                                1.6724   3      .6431       Homogenous
  MACE                              3.1045   2      .2118       Homogenous
  Cardiac death                     0.8357   3      .8357       Homogenous
  All-cause death                   3.1045   2      .2118       Homogenous
  Stent thrombosis                  0.2858   3      .9627       Homogenous
  Target vessel revascularization   6.7677   3      .0797       Homogenous
  Target lesion revascularization   5.8443   2      .0538       Homogenous

*dF*: degrees of freedom.

###### 

Baseline characteristics of patients in included studies.

                          Chevalier et al.   Choi et al.       Kim et al.   Park et al.    Leon et al.
  ----------------------- ------------------ ----------------- ------------ -------------- ---------------
  Number studied                                                                           
   PES                    197                153               105          884            775
   ZES                    199                86                47           883            773
  Age                                                                                      
   PES                    63 +/− 11          61.54 +/− 12.22   63 +/− 9     62.0 +/− 9.6   63.6 +/− 11.0
   Zes                    63 +/− 10          60.24 +/− 11.76   59 +/− 12    61.7 +/− 9.3   63.5 +/− 11.1
  Gender (male)                                                                            
   PES                    77%                100 (65.4%)       76 (72.4%)   582 (65.8%)    531 (68.5%)
   ZES                    75%                69 (80.2%)        37 (78.7%)   586 (66.4%)    517 (66.9%)
  Vessel location (LAD)                                                                    
   PES                    40%                72 (47.1%)        45 (42.9%)   611 (50.7%)    321 (41.5%)
   ZES                    48%                45 (52.3%)        30 (63.8%)   622 (52.3%)    326 (42.2%)
  Vessel location (LCx)                                                                    
   PES                    19%                29 (19.0%)        15 (14.2%)   253 (21.0)     202 (26.1%)
   ZES                    24%                10 (11.6%)        2 (4.3%)     252 (21.2%)    208 (26.9%)
  Vessel location (RCA)                                                                    
   PES                    41%                52 (34.0%)        45 (42.9)    340 (28.2%)    251 (32.4%)
   ZES                    28%                31 (36.0%)        15 (31.9%)   316 (26.6)     238 (30.8%)
  Diabetes mellitus                                                                        
   PES                    26%                104 (68.0%)       23 (21.9%)   245 (27.7%)    236 (30.5%)
   ZES                    22%                64 (74.4%)        12 (25.5%)   268 (30.4%)    241 (31.2%)
  Hypertension                                                                             
   PES                    67%                86 (56.2%)        50 (47.6%)   540 (61.1%)    640 (82.6%)
   ZES                    69%                53 (61.6%)        20 (43.5%)   552 (62.5%)    614 (79.4%)
  Hyperlipidemia                                                                           
   PES                    72%                104 (68.2%)       43 (41.3%)   446 (50.5%)    657 (84.8%)
   ZES                    78%                57 (66.3%)        18 (39.1%)   466 (52.8%)    629 (81.4)

PES: paclitaxel-eluting stent; ZES: zotarolimus-eluting stent; LAD: left anterior descending coronary artery; LCx: left circumflex coronary artery; RCA: right coronary artery.
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